NYSEMKT: AEONAeon Biopharma Inc Stock
$0.78-0.02 (-2.5%)
Updated Aug 14, 2025
AEON Price
$0.78
Fair Value Price
N/A
Market Cap
$908.22k
52 Week Low
$0.38
52 Week High
$115.57
P/E
-0.11x
P/B
-0.06x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$1.64M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.74
Operating Cash Flow
-$14M
Beta
0.19
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AEON Overview
Priveterra Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to acquire companies in the medical technology sector. The company was incorporated in 2020 and is based in Fort Lauderdale, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AEON's potential to beat the market
- AEON doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AEON
RankedUnranked of 481
RankedUnranked of 481
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $12.94 | A | |
| $12.09 | A | |
| $37.89 | A |
Be the first to know about important AEON news, forecast changes, insider trades & much more!
AEON News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AEON scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AEON is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AEON is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
AEON's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more AEON due diligence checks available for Premium users.
Valuation
AEON price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.11x
Industry
-116.18x
Market
36.29x
AEON price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.06x
Industry
4.42x
AEON's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.6M
Profit Margin
0%
AEON's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$11.7M
Liabilities
$27.5M
Debt to equity
-1.74
AEON's short-term assets ($10.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AEON's long-term liabilities ($18.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AEON's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AEON's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.1M
Investing
$0.0
Financing
$84.0k
AEON's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AEON vs Biotech Stocks
Aeon Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.